{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:09:15Z","timestamp":1648973355916},"reference-count":11,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Nintedanib zur Behandlung der SSc-ILE\u2002Nintedanib reduziert den j\u00e4hrlichen Abfall der forcierten Vitalkapazit\u00e4t (FVC) bei Patienten mit interstitieller Lungenerkrankung (ILE) in Assoziation mit einer systemischen Sklerose (SSc) und ist in dieser Indikation neu zugelassen.<\/jats:p><jats:p>\n          Nintedanib zur Behandlung der chronischen progredient fibrosierenden ILE\u2002In der INBUILD-Studie wurde Nintedanib bei Patienten mit chronischer progredient fibrosierender ILE (Non-IPF) untersucht. Eingeschlossen waren Patienten mit exogen allergischer Alveolitis (EAA), idiopathischer nichtspezifischer interstitieller Pneumonie (iNSIP), unklassifizierbarer idiopathischer interstitieller Pneumonie, ILE bei rheumatoider Arthritis, SSc-ILE, expositionsassoziierter ILE, ILE bei Mischkollagenose, Sarkoidose und anderen fibrosierenden ILE. Nintedanib f\u00fchrte auch in dieser Patientengruppe zu einer signifikanten Reduktion des j\u00e4hrlichen FVC-Abfalls. Zus\u00e4tzlich zur Therapie der IPF und der SSc-ILE ist Nintedanib jetzt auch zur Behandlung anderer chronischer progredient fibrosierender ILE zugelassen.<\/jats:p><jats:p>\n          Pirfenidon bei Non-IPF-ILE\u2002Pirfenidon wurde ebenfalls bei Patienten mit progredienter Non-IPF-Lungenfibrose untersucht. In der finalen Analyse der RELIEF-Studie konnte ein signifikant positiver Effekt auf den Verlauf der FVC durch die Pirfenidon-Behandlung nachgewiesen werden. Eine Zulassung in dieser Indikation liegt bisher nicht vor. Im Rahmen einer Phase-II-Studie wurde Pirfenidon bei unklassifizierbarer progredienter ILE untersucht. Die Lungenfunktionsmessung im Zentrum (sekund\u00e4rer Endpunkt) ergab eine signifikante Abschw\u00e4chung des FVC-Verlusts nach 24 Wochen in der mit Pirfenidon behandelten Gruppe versus Placebo. Eine Zulassung in dieser Indikation liegt bisher ebenfalls nicht vor.<\/jats:p>","DOI":"10.1055\/a-1239-3728","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T23:31:34Z","timestamp":1611963094000},"page":"181-184","source":"Crossref","is-referenced-by-count":1,"title":["Antifibrotische Therapie \u2013 neue Indikationen bei Non-IPF-interstitiellen Lungenerkrankungen"],"prefix":"10.1055","volume":"146","author":[{"given":"Philipp","family":"Markart","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Campus Fulda, Universit\u00e4tsmedizin Marburg"},{"name":"Medizinische Klinik und Poliklinik 2, Universit\u00e4tsklinikum Gie\u00dfen"},{"name":"Biochemisches Institut, Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotios","family":"Drakopanagiotakis","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Campus Fulda, Universit\u00e4tsmedizin Marburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Wygrecka","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik 2, Universit\u00e4tsklinikum Gie\u00dfen"},{"name":"Biochemisches Institut, Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"W D Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"370","author":"L Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis","volume":"370","author":"T E King","year":"2014","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"O Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"ref5","first-page":"A1525","article-title":"Effect of nintedanib in patients with limited and extensive Systemic Sclerosis\u2013Associated Interstitial Lung Disease: data from the SENSCIS trail","volume":"201","author":"N Goh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","first-page":"A4558","article-title":"Effect of nintedanib on progression of systemic sclerosis associated interstitial lung disease (SSc-ILD) beyond 52 weeks: data from the SENSCIS trail","volume":"201","author":"T Maher","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung disease","volume":"381","author":"K R Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"A U Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) \u2013 a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"J Behr","year":"2017","journal-title":"BMC Pulm Med"},{"key":"ref10","first-page":"RCT1879","article-title":"Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF)","volume":"54","author":"A Guenther","year":"2019","journal-title":"Eur Resp J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trail","volume":"8","author":"J Maher","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1239-3728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T23:32:46Z","timestamp":1611963166000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1239-3728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":11,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,1,29]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1239-3728","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}